Overview

A class action lawsuit has been filed against Inspire Medical Systems, Inc. (“Inspire” or the “Company”) and certain of the Company’s former senior executive officers alleging violations of the federal securities laws. The Company’s common stock trades on the New York Stock Exchange (“NYSE”) under the ticker symbol “INSP”.

The Inspire class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired common stock of Inspire between August 6, 2024, through August 4, 2025, both dates inclusive, (the “Class Period”).

The lawsuit alleges that Inspire Medical Systems, Inc. and its senior executives misled investors about the launch and commercial success of the company’s new sleep apnea device, Inspire V. Inspire develops and manufactures implantable medical devices for the treatment of obstructive sleep apnea, and the Inspire V system—featuring an implanted sensor and neurostimulator—was promoted as a major advancement expected to drive significant revenue growth and strengthen the company’s competitive position. Because Inspire V represented the company’s most important new product, investors were closely watching its development and rollout.

According to the lawsuit, throughout the class period, defendants made materially false and misleading statements assuring investors that Inspire had met all regulatory, technical, and commercial requirements for a successful launch, that demand for Inspire V was strong, and that the rollout was proceeding well. In reality, the launch was deeply troubled. Demand for Inspire V was weak because customers already had excess inventory of older versions of the device, and the company failed to take necessary steps to ensure clinician training or insurance payor adoption. These shortcomings led to significant delays in product uptake and widespread distribution problems.

The truth came to light on August 4, 2025, when Inspire disclosed the serious issues surrounding the Inspire V rollout. Following this announcement, the company’s stock price fell 32 percent, wiping out more than $1.5 billion in shareholder value. The lawsuit alleges that, as a result of the defendants’ false and misleading statements and omissions, investors suffered significant losses once the problems with Inspire V were revealed.

*          *          *

If you purchased or otherwise acquired common stock of Inspire between August 6, 2024, through August 4, 2025, both dates inclusive, (the “Class Period”), you may be eligible to serve as lead plaintiff in this lawsuit. If you invested in Inspire securities and wish to seek appointment as lead plaintiff, we encourage you to contact DiCello Levitt LLP by submitting your information through the form on this page.

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as lead plaintiff in the Inspire class action lawsuit is January 5, 2026.